On October 5, 2022 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, reported the Company will present new data on its growing portfolio of clinical-stage immuno-oncology programs at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, to be held November 8-12 in Boston, MA and virtually (Press release, Agenus, OCT 5, 2022, View Source [SID1234621728]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New data on multiple expansion cohorts from the Phase 1 study of botensilimab (a multifunctional Fc-enhanced anti-CTLA-4) in cold (immunotherapy-resistant) tumors will be presented at an oral plenary session on novel immunotherapies on Saturday, November 12th at 10:50am ET. Three additional presentations will include new data on the mechanisms underpinning botensilimab’s differentiated and enhanced anti-tumor immunity and provide an overview of the Phase 2 trial in progress of AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody in combination with balstilimab (anti-PD-1) in advanced pancreatic cancer.

Separately, Agenus announced today that Dhan Chand, PhD, Head of Drug Discovery at Agenus was selected to present on the topic of enhanced CTLA-4 blockade at the SITC (Free SITC Whitepaper) Targets for Cancer IO Deep Dive Series on Wednesday, October 5, from 2:00 pm – 4:00 pm ET. To register for the webinar, please visit the Educational and Scientific Programs section of the SITC (Free SITC Whitepaper) website. Dr. Chand’s selection to participate through a highly competitive process underscores his leadership and highlights the focus on botensilimab, as well as the field’s appreciation for the important role CTLA-4 plays in anti-tumor immunity and the scientific contributions and understanding advanced by the team at Agenus.

Presentation Details:

Abstract Title: Botensilimab, a Novel Innate/Adaptive Immune Activator, plus or minus Balstilimab (Anti-PD-1) in "Cold" and I-O Refractory Metastatic Solid Tumors (NCT03860272)
Abstract Number: 778
Presenting Author: Breelyn Wilky, MD, Director of Sarcoma Medical Oncology, Deputy Associate Director for Clinical Research, University of Colorado Medicine
Details: Session 302: Thomas Waldmann Memorial Plenary Session: New Immunotherapies, 11/12/2022, 9:55am – 11:25am ET

Abstract Title: Botensilimab, an Fc-enhanced CTLA-4 Antibody, Enhances Innate and Adaptive Immune Activation to Promote Superior Anti-Tumor Immunity in "Cold" and I-O Refractory Tumors
Abstract Number: 470
Presenting Author: Daniel Levey, PhD, Senior Director Vaccine Research, Agenus
Details: Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

Abstract Title: Botensilimab Modulates Innate and Adaptive Gene Expression Programs Resulting in Superior Immune Stimulation Relative to a First-Generation Anti-CTLA-4 Antibody
Abstract Number: 941
Presenting Authors: Shanmugarajan Krishnan, PhD, Vision Scientist II, Agenus; Jacky Chow, PhD, Senior Scientist, Agenus
Details: Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

Abstract Title: Phase 2 trial of AGEN1423, an Anti-CD73-TGFβ-Trap Bifunctional Antibody, in Combination with Balstilimab, with or without Chemotherapy in Subjects with Advanced Pancreatic Cancer
Abstract Number: 651
Presenting Author: Bruno Bockorny, MD, Assistant Professor, Medicine, Harvard Medical School
Details: Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

Complete abstracts will be released on Monday, November 7, 2022 at 8:00am ET. Updated data presented at the conference will be available to view in the Publications section of the Agenus website (View Source) following the SITC (Free SITC Whitepaper) Annual Meeting.